Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
JAK2 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
14 July 2026
A visual target evaluation report for JAK2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
JAK1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
14 July 2026
A visual target evaluation report for JAK1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
IL6R 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
14 July 2026
A visual target evaluation report for IL6R, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
IL6 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
14 July 2026
A visual target evaluation report for IL6, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
BCL2L1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
BCL2L1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
MCL1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
MCL1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
BCL2 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
BCL2 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
MDM2 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
MDM2 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
TP53 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
TP53 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
BRCA2 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
BRCA2 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
BRCA1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
BRCA1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
PARP2 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
PARP2 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.